Must-Know Guide: UKCA Marking for Medical Devices in 2026 – Key FAQs & Essentials - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > Must-Know Guide: UKCA Marking for Medical Devices in 2026 – Key FAQs & Essentials

Must-Know Guide: UKCA Marking for Medical Devices in 2026 – Key FAQs & Essentials

Time：2026-10-12 11:32:24

The UK medical device regulatory landscape keeps evolving in recent years. Many exporting manufacturers are asking: For market entry in the UK in 2026, should you apply UKCA or CE marking? What are the differences between Great Britain and Northern Ireland? Can products with only FDA clearance be placed on the UK market?Based on the latest updates from MHRA, this article compiles frequently asked questions to help medical device manufacturers clarify compliance routes for the UK market.

一、Two Separate Regulatory Territories

Many companies mistakenly treat the whole UK as one unified regulatory regime. In fact, two independent sets of rules apply:

（一）Great Britain (England, Scotland and Wales)

CE marking or UKCA marking is accepted; a UK Responsible Person (UKRP) must be appointed; devices need registration with MHRA.

（二）Northern IrelandFollows EU regulations. Only CE marking is recognised. UKCA marking and UKRP are not accepted. An EU Authorised Representative is required.

划重点：一套证书不能通吃全英国，布局英国市场务必区分地域。

二、Answers to Top Overseas Market Access Questions

Q1：Which medical devices are mandatorily required to bear UKCA marking in September 2026?

A：UKCA marking is NOT mandatory for all products.

At present, UKCA is required only when both conditions below are met:

The product does not hold a CE certificate;
The manufacturer intends to place the device on the Great Britain market.

If your device already has CE marking, it can still be marketed in Great Britain. However, this does not mean immediate sales. You still need to fulfil three core obligations:

Appoint a UK Responsible Person (UKRP)
Complete device registration in the MHRA database (separate from EU EUDAMED)
Comply with post-market surveillance and vigilance reporting requirements under SI 2024/1368

Q2：When is a UK Approved Body required?

A：A UK Approved Body is the UK equivalent of an EU Notified Body. Several organisations hold both EU and UK notified/approved body statuses.

Products that may self-declare UKCA without a UK Approved Body:

Class I non-sterile, non-measuring medical devices
Non-self-test IVDs not listed in Annex II A/B

All other risk classes of products require conformity assessment by a UK Approved Body if you choose the UKCA route.

Note: No UK Approved Body involvement is needed if you take the CE route.

Q3：Two market access routes for 2026: CE vs UKCA

A：Two compliance pathways are available for Great Britain, either is acceptable:

UKCA marking only: Valid for Great Britain sales only; not accepted in the EU or Northern Ireland.
CE marking: Covers Great Britain, EU27, Iceland, Liechtenstein, Norway and Northern Ireland.

Manufacturers may also hold both CE and UKCA marks simultaneously.

What are the practical benefits of obtaining UKCA voluntarily?

The current UK MDR 2002 derives from the old EU Directive 93/42/EEC. Its classification rules differ from the current EU MDR/IVDR.

Some medical device software
Certain matrix-based wound care products
Reusable Class I surgical instruments
Most IVDs

Many manufacturers leverage this window: complete UKCA self-declaration to launch in Great Britain quickly, while working on EU MDR certification which often takes more than one year.

MHRA is revising UK medical device regulations. This favourable window is limited. Devices certified under current rules will benefit from transition periods after the new regulations take effect.

Q4：MHRA registration is still required even with a valid CE certificate?

A：Yes, mandatory!Regardless of UKCA or CE marking, including custom-made devices, IVDs, systems and procedure packs, all products placed on Great Britain market must register with MHRA.

Registration submitter:

Non-UK manufacturers: registration must be submitted by the UKRP
UK-based manufacturers: can submit registration themselves

Registration attracts annual fees. The first-year fee is prorated based on registration date; subsequent annual fees are due on 1 April each year.

Q5：Will CE marking be recognised permanently?

A：MHRA previously ran a public consultation on whether to continue recognising CE certificates or require simplified assessment by UK Approved Bodies. The consultation closed in April 2026, but MHRA has not released final conclusions as of September 2026.

Current status: CE marking remains valid, but future policy carries uncertainty. Manufacturers need to monitor MHRA announcements continuously.

Q6：Can FDA approval alone enable direct UK market launch?

A：Not at this stage. Great Britain currently accepts only UKCA and CE marking. FDA clearance/approval cannot be used directly for placing devices on the UK market.Nevertheless, MHRA is developing the International Reliance Framework. Once new regulations enter into force: Devices approved by US FDA, Australia TGA and Canada Health Canada may access the UK via a simplified assessment route, without full re-certification, subject to certain restrictions.

Q7：When will the revised UK regulations take effect?

A：Draft revised regulations were published in May 2026, with public consultation closing in June. MHRA is now reviewing industry feedback before submitting the statutory instrument to Parliament.

Timeline: Parliament approval → official publication → 6 months after publication for entry into force. Transition periods will apply to certain requirements.

Major changes brought by the new regulations:

Reclassification of medical devices and IVDs aligned with international standards
Mandatory UDI implementation
Rollout of the international reliance assessment pathway (FDA / TGA / Canada)

三、Practical Recommendations for Export Manufacturers

Clarify sales territories: Great Britain follows CE/UKCA + UKRP; Northern Ireland requires CE + EU REP. Do not mix the two regimes.
For holders of valid CE certificates: UKRP appointment and MHRA registration are both compulsory.
EU MDR certification has long lead times. Evaluate whether to use the existing regulatory window for UKCA self-declaration to enter Great Britain early, while preparing for regulatory changes ahead.
Products with only FDA clearance: cannot enter UK for now; follow updates on the International Reliance Framework.
Keep tracking MHRA consultation outcomes, as CE recognition policy remains subject to change.

四、Conclusion

The UK medical device compliance framework is undergoing a critical transition between old and new rules. Shifting policies, territorial distinctions and multiple certification routes create compliance dilemmas and planning challenges for exporting manufacturers. At present, CE marking remains usable, UKCA self-certification offers a valuable window of opportunity, and the new international reliance rules are forthcoming, bringing both opportunities and uncertainties. For medical device enterprises targeting the UK market, blind certification or compliance by chance is not advisable. Clearly distinguish regulatory.若需要进一步了解，欢迎咨询 Wiselink 知汇！

Previous：Understanding MDCG 2020‑16 rev.2 | Core Guidance on IVD Product Classification under EU IVDR Next：FDA Update! 14 Classes of Class II Toxicology Testing Systems Qualify for 510(k) Exemption!

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.